Cryoglobulinemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Feham Tariq (talk | contribs) No edit summary |
Feham Tariq (talk | contribs) |
||
| Line 13: | Line 13: | ||
*:* Interferon-alfa and ribavirin have been used in combination. | *:* Interferon-alfa and ribavirin have been used in combination. | ||
* MC response, predictably, was related to the response rate of the underlying HCV to these agents. | * MC response, predictably, was related to the response rate of the underlying HCV to these agents. | ||
* Ribavirin should not be used in patients with glomerular filtration rate (GFR) <50 cc/min. | * Ribavirin should not be used in patients with glomerular filtration rate (GFR) <50 cc/min. | ||
==References== | ==References== | ||
Revision as of 00:01, 30 April 2018
|
Cryoglobulinemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryoglobulinemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Cryoglobulinemia medical therapy |
|
Risk calculators and risk factors for Cryoglobulinemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Feham Tariq, MD [2]
Overview
Medical Therapy
The medical treatment of cryoglobulinemia depends on the underlying etiology, nature and progression of the disease. The main indication for therapy is progressive end organ disease affecting the kidneys, skin, gastrointestinal system, central nervous system and the extremities.
Acute Pharmacotherapies
- Outside of the acute setting, immunosuppresive agents are thought to worsen the course of MC associated with HCV.
- Interferon-alfa and ribavirin have been used in combination.
- MC response, predictably, was related to the response rate of the underlying HCV to these agents.
- Ribavirin should not be used in patients with glomerular filtration rate (GFR) <50 cc/min.